en.Wedoany.com Reported - On May 20, 2026, Aphranel® held its first anniversary celebration at the Waldorf Astoria Shanghai on the Bund, showcasing the brand's latest advancements in the field of regenerative aesthetics.
On May 8, 2025, Aphranel® made its global debut in Shanghai, following the company's receipt of China's first Class III license for an injectable facial filler based on calcium hydroxylapatite (CaHA) microspheres. Within its first year on the market, the brand cumulatively delivered over 150,000 units across China, covering 28 provinces and 94 cities, partnering with more than 620 medical clinics, and training and certifying over 700 physicians.
At the anniversary summit, Aphranel® announced that it had obtained certification under the European Union Medical Device Regulation (EU-MDR, EU 2017/745), becoming the first injectable facial filler researched, developed, and manufactured in China to receive this certification, and also the first CaHA microsphere injectable facial filler from the Asia-Pacific region to do so. The certification process took 2 years and 7 months, following the Class III procedure for absorbable implantable medical devices, with over 6,381 pages of technical documentation submitted, more than 120 internal review meetings held, and completion in collaboration with the UK notified body BSI.
Shanghai Moyom, the biotechnology company behind Aphranel®, has accumulated 12 years of research experience in CaHA microsphere structure, degradation pathway validation, and regenerative biomaterial development. At the celebration, the brand launched its second flagship product, Aphranel® MagicCrystal Arc™.
Professor Yuan Tun from the National Engineering Research Center for Biomaterials at Sichuan University presented preliminary results on the in vivo degradation kinetics and tissue remodeling mechanisms of Aphranel® CaHA microspheres. A multidisciplinary roundtable was also held on-site to discuss biomaterial innovation, regenerative medicine, and clinical applications.
Aphranel® concurrently launched "The Norns' Plan," a global academic initiative aimed at fostering collaboration and knowledge exchange in the field of regenerative aesthetics, promoting international medical education, joint research, and global clinical dialogue. The brand signed cooperation agreements with medical experts from Europe, the Middle East, and the Asia-Pacific region, and established a strategic partnership with Langjiu Manor.
At the event, immersive art installations inspired by butterflies, architecture, and time transformed the hotel space into a sensory experience embodying the brand's philosophy, "Poetics of Time." Aphranel® stated that it will expand into markets in Europe, Latin America, the Middle East, and Southeast Asia in the future, and will continue to invest in scientific research related to regenerative aesthetics.
Aphranel® founder Guangming Lin stated at the event: "Willingness to wait is the ultimate hallmark of a long-termist brand."
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
